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Vigabatrin (gamma-vinyI-GABA or GVG) is an irreversible inhibitor of gamma-aminobutyric acid transaminase 
(GABA-T), which is an enzyme responsible for gamma-aminobutyric acid (GABA) catabolism. Inhibition of 
GABA catabolism increases brain concentration f GABA, a neural inhibitor. GVG has been found to be a potent 
new anti-epileptic drug, especially in the treatment of refractory epilepsy, in particular of complex partial seizures. 
Three patients who developed a severe status epilepitcus while on GVG treatment are reported. 
A possible proconvulsive effect of GVG is hypothesized, which might result from disinhibition in the 
nigro-collicular pathway due to increased GABA-levels. 
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INTRODUCTION 
Vigabatrin (gamma-vinyl-GABA or GVG) is the 
first rationally-developed drug against epileptic 
seizures available I. GVG is a selective, enzyme- 
activated, irreversible inhibitor of GABA- 
transaminase, the enzyme which is primarily 
responsible for the catabolism of gamma- 
aminobutyric acid (GABA) 2. The inhibition of 
GABA catabolism by GVG increases brain 
concentration of GABA, an important inhibiting 
neurotransmitter. Several studies suggest hat an 
increase of brain GABA protects against 
seizures 3.
GVG is indicated in the treatment of refractory 
epilepsy and in particular of refractory complex 
partial seizures in adults and children and of 
infantile spasms/atonic myoclonic attacks in 
children 4. Adverse effects are hyperkinesia espe- 
cially in mentally retarded children, somnolence 
and weight increase. 
Most adverse effects are seen in the early 
treatment phase while chronic treatment adverse 
reactions are uncommon 5. 
CASE REPORTS 
We report on three cases with a status epilepticus 
(SE) during GVG therapy. 
The first patient is a 17-year-old female, whose 
pregnancy and birth were uneventful. At the age 
of 15 months he was said to have had a 'flu', after 
which a regression of her motor and intellectual 
skills was noticed. At the age of 5, she suffered 
from a viral meningitis. At that time a spastic 
tetraparesis, symptomatic generalized epilepsy 
with generalized continuous clonic movements, 
periods of impaired consciousness and a moder- 
ate mental handicap were seen. Her medical 
treatment was sodiumvalporate (VPA) 
900 rag/day and clonazepam (CZP) 0.5 rag/day. 
At the age of 12, after several nights with 
partial sleep deprivation, she had a tonic-clonic 
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SE during a disco party (for which she had to be 
admitted to a hospital), which was stopped by 
CZP intravenously. After being discharged, her 
medical treatment was continued unchanged. At 
the age of 17, she developed a partial epileptic 
seizure, involving jerking of the right arm and 
jerky eye movements. As a result of secondary 
generalization of this seizure she had to be 
hospitalized. Administration of diazepam (20 mg 
by rectiole), CZP (Tmg iv.) and phenytoin 
(DPH) (iv. loading dose 600mg and a main- 
tenance dose of 200 rag/day, bloodlevel 14 mg/l) 
showed no effect, so a thiopentone coma with 
burst suppression activity on the EEG was 
induced. CT-scan of the brain and examination of
cerebrospinal f uid were normal. After 1 day 
thiopentone tapering was begun over a period of 
5 days. Her medication was then DPH 
(200mg/24 hours, later reduced to 75mg/24 
hours) and, if necessary, CZP. Phenobarbitone 
(PB 200mg/day) was added because of con- 
tinuous clonic movements with corresponding 
spike wave complexes in the EEG. After this, 
treatment with GVG (2z500mg/day, later 
2 × 1 000mg/day), was started and DPH was 
stopped at the same time. During the next 19 days 
she improved and was better than ever before, 
the clonic movements almost disappearing. PB 
was tapered with 25 mg because of drowsiness. 
Then she had a partial seizure which evolved to a 
generalized convulsive SE. Neither CZP (6mg 
intravenously), nor diazepam (10mg intra- 
venously) nor sodiumvalproate (1200mg in- 
travenously) were successful. Again a thiopen- 
tone coma (with a suppression-burst pattern on 
the EEG) had to be induced. Flunarizine 
(10 mg/day) was added to the medication because 
of persisting myoclonic activity. GVG was 
tapered over 5 days. Thiopentone (100- 
200 mg/hour) was administered over a period of 
15 days and tapered over 6 days. PB was 
increased (to 300 mg/day) and CZP was adminis- 
tered at a maintenance dose of 3 mg/day. She 
regained consciousness lowly but still showed 
some clonic movements. At that time, she was 
worse than before admission, unable to com- 
municate verbally and wheelchair bound. She was 
transferred to a daycare rehabilitation centre. 
Screening of blood and a 24 hour sample of 
urine for abnormal metabolites was negative. 
EMG and nerve conduction tests revealed axonal 
polyneuropathy. Her condidion worsened and 
without warning she died, supposedly due to 
pneumonia. Autopsy was not allowed and a 
definite diagnosis could not be made. So, a 
tentative diagnosis of neuro-axonal dystrophy 
was made. 
The second case concerns a woman with M. 
Von Recklinghausen. At the age of 16 she had a 
left fronto-parietal fibro-sarcoma removed and 
subsequent radiotherapy. Soon afterwards he 
had a simple partial seizure (with clonic move- 
ments of her right hand and right corner of the 
mouth). Treatment with DPH (450 mg/day) and 
carbamazepine (CBZ) (600 mg/day) was success- 
ful. At the age of 24, seizures reappeared, DPH 
was replaced by GVG (1 500mg/day) an the 
CBZ dose was raised to 800mg/day. A few 
months later she had a seizure with a post-ictal 
right-sided paresis of arm and face. During this 
seizure she remained conscious. The EEG 
showed focal epileptic activity in the left frontal 
and anterior temporal leads with postictal slowing 
over almost the entire left hemisphere. During 
the next month, she repeatedly had simple partial 
seizures which could be stopped by CZP. The 
CBZ bloodlevel was 8.5 mg/l at that time. 
Seven weeks later she was readmitted due to a 
simple-partial SE alternated by a complex-partial 
SE of several hours duration, due to which she 
became drowsy and was unable to take her AED. 
SE was cut by CZP (8 mg/day). On admission 
CBZ bloodlevel was not assessed. She was loaded 
with 1 100mg DPH intravenously (bloodlevel 
10mg/l) and transferred to the intensive care 
unit. The next day her CBZ bloodlevel was 
7.5 mg/l on a dose of 800 mg/day. This partial SE 
recurred daily during 10 days in spite of DPH 
levels ranging from 10 to 20 mg/l and CBZ levels 
of 6.5 to 9.5 mg/l. Five days after admission GVG 
was stopped. At that time she was on CBZ 
(1 200 rag/day, bloodlevel 6.5 mg/l), CZP 
(8mg/day) and DPH (400mg/day, bloodlevel 
10 mg/I). She had no further seizures four days 
after stopping GVG and was discharged in a good 
clinical condition. However she continued to have 
low frequent seizures (simple partial alternated 
by complex partial fits) on DPH 300 mg (blood- 
level 13mg/1) and controlled release CBZ 
1 200 mg (bloodlevel 8mg/1) and CZP 2 mg. 
The third case concerns a 33-year-old, mentally 
handicapped (IQ 40), female patient, who had 
symptomatic generalized epilepsy with tonic- 
clonic and complex partial seizures from the age 
of four years. She had never before had a SE. 
While on oxcarbazepine (OCB) 1 500mg/day 
and clobazam 20mg/day, the frequency of the 
(mainly complex partial) seizures was on average 
0.5-1.0 per 24 hours. GVG was started with 
1 000mg/day and raised in 2 weeks to 2000 
mg/day. At the same time OCB was tapered with 
1 tablet/week for 5 weeks. Sixteen days after the 
institution of GVG, while on 2 000 mg GVG and 
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300 mg OCB, she developed serial tonic-clonic 
seizures, which eventually evolved to a 13 
hour-long generalized convulsive SE, despite 
rectally administered diazepam (8 x 10 mg.) and 
CZP (2 x 2 mg intravenously). On admission she 
still had a generalized convulsive SE. Midazolam 
(15 mg intramuscularly), CZP (4 mg intravenous 
loading dose and 1 mg/hr continuous intravenous 
infusion) and DPH (1 100 mg intravenous loading 
dose, bloodlevel 20mg/l) were found to be 
unsuccessful in the hours after admission. So, 
after intubation, propofol was started (50mg 
intravenous loading dose in three minutes, 
6mg/hour continous intravenous infusion) and 
the SE ceased. Mechanical ventilation was not 
necessary. Because no other cause or precipitat- 
ing factor for the status could be found, GVG was 
discontinued. 
DISCUSSION 
Exacerbation of seizures due to anti-epileptic 
drugs (AED), though adequate for the specific 
seizure type has been described only occasionally. 
Toxic serum levels of DPH may increase seizure 
frequency or even precipitate SE% Administra- 
tion of benzodiazepines may result in an aggrava- 
tion of tonic seizures in symptomatic generalized 
epilepsy v's. CBZ has been reported to induce 
absences, myoclonic, tonic and generalized se- 
izures as well as absence status '~")'j~. On the 
whole, a frank deterioration like SE due to 
commonly used anti-epileptic drugs is very 
unusual. 
Recently four cases of complex partial SE with 
a duration of 5-14 days have been described in 
patients on GVG t2  `as well as stupor and 
myoclonic jerks in a patient during GVG 
treatment, which disappeared after discontinua- 
tion of GVG 13. 
Another (retrospective) study on 57 patients on 
GVG as comedication reports five patients who 
developed SE after 2-8 months of GVG treat- 
ment. Two of them had their original AED 
reduced or stopped (but were seizure free two 
and eight months on this regime), a third patient 
with cerebral metastasis had SE two days before 
he died due to cerebral herniation. In the 
remaining two patients no clear cause would be 
detected za. 
The three patients described in our case report 
also developed SE during GVG treatment. 
Remarkably, the SE only disappeared after GVG 
was discontinued. To explain these phenomena 
we hypothesize about a possible mechanism. 
GABA transmission plays a key role in 
controlling seizure activity in rats ~. Function and 
effect of GABA depends on the anatomic site of 
the GABA enhancement. There is a GABA-ergic 
pathway from substantia nigra (SN) pars re- 
ticularis to the tectum cells (the nigro-collicular 
pathway). In rats, activation of certain neurons in 
the tectum is anti-convulsant. When GABA is 
elevated and GABA-transmission is enhanced in 
the SN, the nigro-collicular GABA neurons are 
inhibited and consequently turn off the GABA 
that goes to the tectum. This results in a 
disinhibition (i.e. activation) of target cells in the 
tectum where the GABA-level increases (anti- 
convulsive effect). Conversely, if GABA- 
transmission i the nigro-collicular pathway were 
to increase, the opposite effect would be 
achieved, i.e. suppression of target ceils in the 
tectum to produce a proconvulsive condition. 
Therefore, while GABA elevation in the SN is 
anticonvulsive, GABA elevation in the nigro- 
collicular pathway is proconvulsive. 
In the same way, a disinhibition of the principal 
excitatory neurons of the hippocampal formation 
due to increased inhibitory neurons in the 
hippocampus (as seen in seizure sensitive gerbils 
during GVG treatment) is postulated to result in 
focal seizure activity within the hippocampus and 
seizure generalization through multiple synaptic 
connections ~5. 
GVG is a strong irreversible inhibitor of 
GABA-transaminase by which it increases the 
GABA level in the brain. Injury in the SN pars 
reticularis could result in a dysregulation of this 
mechanism, so GVG could have a proconvulsive 
effect instead of the intended anticonvulsant 
effect t. 
After a certain time during SE, in rats cerebral 
damage in vulnerable areas is seen. The neurons 
in the SN pars reticularis are effected after 30 
minutes of continuous SE despite control of 
blood pressure, ventilation and blood pH. After 
45-60 minutes, damage occurs in the third and 
fourth cortex layer and specific areas of the 
hippocampus. In the SN this damage is probably 
the result of a huge energy deficiency and 
excessive lactate accumulation ~6"j7. 
The three patients concerned all had refractory 
epilepsy and more or less severely damaged 
brains. In addition to her neurological handicap, 
the first patient went through two earlier SE. The 
second patient has been operated for a fib- 
rosarcoma of the brain with subsequent radio- 
therapy. Moreover, in neurofibromatosis type 1, 
migrational disturbances are seen TM. The third 
patient has a severe mental handicap and 
refractory generalized epilepsy with daily se- 
izures, both supposedly due to severe perinatal 
asphyxia. 
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We conclude that although SE. during GVG 
treatment could be a coincidence or due to 
changes in the current anti-epileptic drug treat- 
ment, this proconvulsive ffect could also be 
explained by a disinhibition at the SN pars 
reticularis level, as described by this case report, 
or by disinhibition of excitatory neurons of the 
hippocampal formation. 
A possible proconvulsive effect should be taken 
into account when GVG treatment is considered 
for brain-damaged patients, or when, during 
GVG treatment, reduction in the doses of the 
original anti-epileptic drugs is considered. 
Further study of epileptic patients on GVG is 
required to find out the real nature of the effects 
reported in this paper. 
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